Renaissance Technologies LLC Has $101.82 Million Holdings in Enanta Pharmaceuticals Inc (ENTA)

Share on StockTwits

Renaissance Technologies LLC raised its position in Enanta Pharmaceuticals Inc (NASDAQ:ENTA) by 4.0% during the second quarter, HoldingsChannel.com reports. The fund owned 878,500 shares of the biotechnology company’s stock after purchasing an additional 33,600 shares during the quarter. Renaissance Technologies LLC’s holdings in Enanta Pharmaceuticals were worth $101,818,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Meadow Creek Investment Management LLC purchased a new position in shares of Enanta Pharmaceuticals in the first quarter valued at about $110,000. SG Americas Securities LLC purchased a new position in shares of Enanta Pharmaceuticals in the first quarter valued at about $112,000. Riverhead Capital Management LLC purchased a new position in shares of Enanta Pharmaceuticals in the first quarter valued at about $129,000. Glen Harbor Capital Management LLC purchased a new position in shares of Enanta Pharmaceuticals in the first quarter valued at about $140,000. Finally, Sei Investments Co. increased its position in shares of Enanta Pharmaceuticals by 63,966.7% in the first quarter. Sei Investments Co. now owns 1,922 shares of the biotechnology company’s stock valued at $156,000 after acquiring an additional 1,919 shares during the period. Hedge funds and other institutional investors own 77.59% of the company’s stock.

A number of research firms have issued reports on ENTA. Oppenheimer set a $100.00 price objective on shares of Enanta Pharmaceuticals and gave the company a “hold” rating in a research report on Tuesday, August 14th. Zacks Investment Research cut shares of Enanta Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, August 10th. UBS Group cut shares of Enanta Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Wednesday, August 8th. JMP Securities restated a “buy” rating and issued a $120.00 price objective on shares of Enanta Pharmaceuticals in a research report on Tuesday, July 31st. Finally, BidaskClub lowered shares of Enanta Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, July 24th. Six investment analysts have rated the stock with a hold rating, two have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average price target of $107.60.

Shares of ENTA opened at $87.91 on Friday. The stock has a market cap of $1.72 billion, a PE ratio of 21.04 and a beta of 0.87. Enanta Pharmaceuticals Inc has a 1-year low of $41.83 and a 1-year high of $127.77.

Enanta Pharmaceuticals (NASDAQ:ENTA) last announced its earnings results on Tuesday, August 7th. The biotechnology company reported $0.97 earnings per share for the quarter, missing analysts’ consensus estimates of $0.98 by ($0.01). The company had revenue of $57.26 million for the quarter, compared to the consensus estimate of $56.59 million. Enanta Pharmaceuticals had a net margin of 37.63% and a return on equity of 25.84%. sell-side analysts forecast that Enanta Pharmaceuticals Inc will post 3.56 earnings per share for the current fiscal year.

In other news, Treasurer Paul J. Mellett sold 15,000 shares of Enanta Pharmaceuticals stock in a transaction dated Monday, June 11th. The shares were sold at an average price of $120.57, for a total transaction of $1,808,550.00. Following the sale, the treasurer now owns 88,158 shares of the company’s stock, valued at approximately $10,629,210.06. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Jay R. Luly sold 35,000 shares of Enanta Pharmaceuticals stock in a transaction dated Friday, July 6th. The shares were sold at an average price of $125.24, for a total transaction of $4,383,400.00. Following the sale, the insider now directly owns 625,049 shares in the company, valued at approximately $78,281,136.76. The disclosure for this sale can be found here. Insiders have sold a total of 63,355 shares of company stock worth $7,682,559 in the last ninety days. Insiders own 10.56% of the company’s stock.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, focuses on discovering and developing small molecule drugs for the treatment of viral infections and liver diseases. The company's research and development focuses on disease targets: hepatitis B virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and respiratory syncytial virus.

Featured Story: Asset Allocation, Balancing Your Investments

Want to see what other hedge funds are holding ENTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Enanta Pharmaceuticals Inc (NASDAQ:ENTA).

Institutional Ownership by Quarter for Enanta Pharmaceuticals (NASDAQ:ENTA)

Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply